Ariel Villan's struggle with anxieties and hallucinations from efavirenz shifted dramatically after he switched to dolutegravir, a treatment considered superior due to limited side effects.
The World Health Organization promotes dolutegravir as a first-line HIV medication, highlighting its efficiency and low side effects, distinguishing it from other treatments like efavirenz.
Villan's experience illuminates the potential adverse effects of HIV treatments, specifically the debilitating hallucinations and depression induced by efavirenz, pushing him towards dolutegravir.
In response to patent issues surrounding dolutegravir, the Colombian government issued a compulsory license, allowing for broader access to this vital HIV treatment.
[
Collection
]
[
|
...
]